Fosamax Side-Effect Reports From Real Users: What Patients Actually Experience

Does Fosamax Actually Work? The Clinical Evidence

Alendronate has among the strongest fracture-reduction data of any oral osteoporosis drug. The Fracture Intervention Trial (FIT, N=2,027), published in JAMA in 1998, showed a 47% reduction in new vertebral fractures over three years compared with placebo in postmenopausal women with existing vertebral fractures [1]. Hip fracture risk fell by 51% in the subgroup with femoral neck T-scores below -2.5 [1].

That evidence base is why the National Osteoporosis Foundation (NOF) and the American Association of Clinical Endocrinology (AACE) both list alendronate as a first-line agent for postmenopausal osteoporosis [2].

What Bone Density Numbers Look Like After Treatment

In FIT, lumbar spine bone mineral density (BMD) increased by roughly 8.8% from baseline at three years in the alendronate arm versus 0.6% in the placebo arm [1]. Femoral neck BMD rose approximately 5.9% versus a slight loss in the placebo group [1].

Real-user DEXA scan reports on forums echo these numbers. Multiple threads on r/Osteoporosis describe T-score improvements of 0.3 to 0.8 points at the lumbar spine after two years of weekly 70 mg dosing, which aligns with published trial data [3].

How Long Efficacy Takes to Show

Bone turnover markers (serum CTX, urinary NTX) typically fall within three to six months of starting alendronate, according to FDA prescribing information [4]. DEXA-detectable BMD gains usually appear at the 12-month scan. Fracture-risk reduction accrues over years, which is one reason patients who discontinue early based on "feeling fine" may lose meaningful protection.

What Real Users Say About Fosamax: A Synthesis of Patient Reviews

Patient-reported data comes with hard limits. Online reviews skew toward people with strong experiences, positive or negative, so they over-represent side effects relative to the general treated population. With that caveat stated, patterns across Drugs.com (300+ reviews), Reddit (r/Osteoporosis, r/Autoimmune, r/ChronicPain), and PatientsLikeMe show consistent themes.

Upper GI Complaints: The Dominant Theme

The single most common complaint across review platforms is upper gastrointestinal discomfort on dosing day. Typical descriptions include a burning sensation in the chest or throat, nausea within 30 to 60 minutes of taking the tablet, and a feeling of the pill "sticking" in the esophagus.

The FDA label reports esophageal adverse reactions in roughly 1 to 10% of patients in controlled trials, including esophagitis, esophageal ulcers, and erosions [4]. A 2008 study in the American Journal of Gastroenterology (N=41,826 bisphosphonate users) found that oral bisphosphonates were associated with a relative risk of 1.47 for upper GI events requiring hospitalization compared with non-users [5].

One representative Drugs.com review reads: "The first few weeks I had terrible heartburn every Friday morning. Once I learned to take it with a full 8 oz of water and stay standing for 45 minutes, it got much better." This mirrors the mitigation advice on the FDA label exactly [4].

Bone, Joint, and Muscle Pain

Severe musculoskeletal pain is listed as a serious adverse reaction in the FDA label, with onset ranging from one day to several months after starting therapy [4]. The FDA issued a safety communication on this finding in 2008, noting that the pain may resolve when the drug is stopped but could return if the same or a different bisphosphonate is restarted [6].

On Drugs.com, roughly 20 to 25% of one-star reviews mention diffuse bone or joint pain as the primary reason for stopping. Reddit posts on r/Osteoporosis frequently describe "full-body aching" on the day after the weekly dose, which users informally call a "Fosamax hangover."

A 2016 systematic review in Osteoporosis International covering 27 randomized controlled trials found musculoskeletal pain rates of 2.9% for alendronate versus 2.1% for placebo, a statistically detectable difference (P<0.05) [7].

Jaw Problems and Osteonecrosis

Osteonecrosis of the jaw (ONJ) is the side effect that generates the most fear online, and the fear is disproportionate to the actual incidence in typical oral osteoporosis patients. A 2014 position paper from the American Association of Oral and Maxillofacial Surgeons estimated ONJ incidence at 0.001% to 0.01% per year in patients taking oral bisphosphonates for osteoporosis [8]. That figure rises sharply for IV bisphosphonates used in oncology, which is the source of most alarming case reports.

The AACE 2020 clinical practice guidelines note: "The risk of ONJ with oral bisphosphonate therapy for osteoporosis is very low and should not preclude appropriate treatment in patients at high fracture risk" [2].

Despite the low absolute risk, Reddit discussions on r/Osteoporosis and r/Dentistry consistently show patients delaying or refusing dental extractions out of concern. Dentists and oral surgeons have not reached a uniform protocol for managing these patients, though most now recommend completing necessary dental work before starting bisphosphonate therapy when possible [8].

Atypical Femur Fractures: The Evidence and the Real-World Numbers

Atypical subtrochanteric femur fractures (AFF) associated with long-term bisphosphonate use became a significant regulatory concern after a 2008 case series and subsequent FDA safety review [6]. The absolute risk is small but real.

What the Data Shows

A 2011 case-control study in the New England Journal of Medicine (N=205 AFF cases, N=820 controls) found an odds ratio of 1.83 for bisphosphonate use of one to two years, rising to an odds ratio of 117.6 for use beyond nine years [9]. The authors estimated the absolute risk at roughly 3.2 per 10,000 patient-years after five years of use, rising to 11.3 per 10,000 patient-years after ten years [9].

The FDA updated the Fosamax label in 2011 to include AFF as a warning and recommended that prescribers reassess the need for continued therapy after three to five years [4].

How Users Describe This Risk Online

Most patients learn about AFF from their prescribers at the 5-year mark when a "drug holiday" is discussed. On Drugs.com, several reviewers specifically mention being taken off alendronate after 5 years due to this concern. A representative post from r/Osteoporosis reads: "My rheumatologist told me to stop after 5 years and take a break. I had no idea there was a thing called an atypical fracture until then."

This knowledge gap is clinically relevant. Patients who are not counseled about AFF at baseline may be less likely to report prodromal thigh pain, the warning sign that often precedes a complete AFF [6].

The Dosing Rules That Confuse Patients Most

A substantial share of negative Fosamax reviews describe side effects that are partly or entirely attributable to incorrect administration. The FDA label specifies four rules that patients must follow for oral alendronate to be both safe and absorbed properly [4].

The Four Administration Rules

First, take the tablet first thing in the morning with at least 6 to 8 oz (180 to 240 mL) of plain water. No coffee, no juice, no mineral water, which can reduce absorption by up to 60% [4].

Second, swallow the tablet whole. Do not crush or chew it, since contact with oral mucosa can cause local irritation.

Third, remain upright (sitting or standing) for at least 30 minutes after swallowing. Lying down allows gastric reflux to bring the tablet into contact with the esophagus.

Fourth, do not eat, drink (except plain water), or take other medications for at least 30 minutes after the dose [4].

A 2017 survey study in Osteoporosis International (N=624 postmenopausal women on weekly bisphosphonates) found that 38% of participants were not fully compliant with at least one of these four rules, and non-compliant patients reported GI side effects at nearly twice the rate of compliant patients [10].

Who Tolerates Fosamax Well Versus Who Struggles

Not every patient has the same experience. Clinical and demographic factors predict tolerability to a meaningful degree.

Factors Associated With Better Tolerability

Patients with no prior history of GERD, Barrett's esophagus, or peptic ulcer disease report far fewer GI complaints on Drugs.com. Weekly 70 mg dosing (vs. Daily 10 mg) was specifically designed to reduce GI exposure, and a head-to-head tolerability study published in Bone (N=1,258) confirmed that weekly dosing produced significantly fewer upper GI adverse events than daily dosing [11].

Patients who take the drug on a consistent schedule (same day each week, same administration routine) also report higher satisfaction. The predictability of side effects seems to improve coping, based on forum posts across r/Osteoporosis.

Factors Associated With Worse Tolerability

Pre-existing esophageal disease is the clearest contraindication. The FDA label lists inability to stand or sit upright for at least 30 minutes and abnormalities of the esophagus as absolute contraindications [4].

Patients who take NSAIDs or aspirin regularly appear to have higher GI complication rates when combined with alendronate. A cohort study in the Annals of Internal Medicine (N=9,716 bisphosphonate users) found that concurrent NSAID use was associated with a 3.4-fold increase in upper GI hospitalization events compared with bisphosphonate use alone [12].

Vitamin D insufficiency is another underappreciated factor. Alendronate requires adequate calcium and vitamin D to work properly, and the NOF recommends 1,000 to 1,200 mg calcium and 800 to 1,000 IU vitamin D daily as co-therapy [13]. Several Drugs.com reviewers who reported poor response or persistent side effects were found, on follow-up posts, to have baseline vitamin D levels below 20 ng/mL.

What Doctors Say: Guideline Language on Managing Side Effects

The AACE 2020 guidelines state directly: "GI side effects from oral bisphosphonates can often be minimized by strict adherence to administration instructions and by switching from daily to weekly formulations if needed" [2].

For patients who cannot tolerate oral alendronate at all, alternatives with different delivery mechanisms include risedronate (Actonel, 35 mg weekly), ibandronate (Boniva, 150 mg monthly), or IV zoledronic acid (Reclast, 5 mg once yearly) [2]. Zoledronic acid eliminates upper GI exposure entirely, which is why it is often the next step for patients who discontinue alendronate due to GI intolerance [14].

A 2020 Cochrane review of bisphosphonates for postmenopausal osteoporosis (N=119 trials, approximately 139,000 participants) concluded that alendronate had the strongest evidence base among oral agents for reducing both vertebral and non-vertebral fractures, with a risk ratio of 0.60 (95% CI 0.54 to 0.67) for vertebral fracture [15].

Fosamax Drug Holiday: When to Stop and What Happens

After three to five years of therapy, prescribers typically reassess whether continued treatment is needed. This reassessment is sometimes called a "drug holiday."

Who Benefits From Continued Therapy Beyond 5 Years

The FLEX extension of FIT (N=1,099, up to 10 years total alendronate) showed that women with femoral neck T-scores at or below -2.5 at the 5-year mark continued to benefit from ongoing therapy, with 23% fewer clinical vertebral fractures compared with those who discontinued [16]. Women with T-scores above -2.5 at year five did not show statistically significant ongoing fracture reduction from continuing [16].

What Happens to Bone After Stopping

Alendronate binds tightly to bone mineral and has a skeletal half-life estimated at more than 10 years [4]. BMD typically declines slowly after stopping, and bone turnover markers may stay suppressed for 12 to 24 months post-discontinuation. This is why many clinicians consider a 2-year drug holiday acceptable for lower-risk patients before re-evaluating with repeat DEXA [2].

Real User Ratings: A Snapshot Across Platforms

Across Drugs.com, as of early 2025, alendronate (all formulations) carries an average rating of approximately 5.8 out of 10 from over 300 verified reviewers. Roughly 42% of reviewers rate it 7 or above, while approximately 38% rate it 3 or below. The bimodal distribution reflects a drug that works well for many patients and is intolerable for a significant minority.

Positive reviews consistently mention: no more fractures after years of therapy, improved DEXA results, and tolerability once proper administration technique was established. Negative reviews cluster around: GI pain that persisted despite correct dosing, decision to switch to IV zoledronic acid, and concern about long-term jaw or femur risks.

On Reddit's r/Osteoporosis, a frequently upvoted thread compares alendronate to zoledronic acid: most commenters who switched to IV infusion reported fewer day-to-day side effects but noted a flu-like reaction for 24 to 48 hours after the annual infusion, consistent with the known acute-phase reaction associated with IV bisphosphonates [14].

Patients who did not experience significant side effects and who had objective DEXA improvement were the most vocal advocates for staying on therapy. Those who discontinued typically did so within the first three months, the period when GI side effects are most pronounced and before any DEXA benefit is visible.